Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

OBJECTIVE: To assess the incremental cost–utility ratio (ICUR) of gemtuzumab ozogamicin (GO) + standard of care (SOC) vs SOC alone for treatment of patients with de novo AML from a Spanish Health Service perspective. METHODS: A cohort state-transition model, with 12 health-states, was used to estima...

Descripción completa

Detalles Bibliográficos
Autores principales: Mareque, Maria, Montesinos, Pau, Font, Patricia, Guinea, José María, de la Fuente, Adolfo, Soto, Javier, Oyagüez, Itziar, Brockbank, James, Iglesias, Tamara, Llinares, Julia, Sierra, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075179/
https://www.ncbi.nlm.nih.gov/pubmed/33911887
http://dx.doi.org/10.2147/CEOR.S302097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075179/
https://www.ncbi.nlm.nih.gov/pubmed/33911887
http://dx.doi.org/10.2147/CEOR.S302097

Ejemplares similares